242 related articles for article (PubMed ID: 11698280)
1. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.
Caplice NM; Panetta C; Peterson TE; Kleppe LS; Mueske CS; Kostner GM; Broze GJ; Simari RD
Blood; 2001 Nov; 98(10):2980-7. PubMed ID: 11698280
[TBL] [Abstract][Full Text] [Related]
2. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
4. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator.
Pekelharing HL; Kleinveld HA; Duif PF; Bouma BN; van Rijn HJ
Thromb Haemost; 1996 Mar; 75(3):497-502. PubMed ID: 8701415
[TBL] [Abstract][Full Text] [Related]
5. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.
Boffa MB
Atherosclerosis; 2022 May; 349():72-81. PubMed ID: 35606079
[TBL] [Abstract][Full Text] [Related]
6. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins.
Trieu VN; Zioncheck TF; Lawn RM; McConathy WJ
J Biol Chem; 1991 Mar; 266(9):5480-5. PubMed ID: 1848551
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
9. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor.
Stalboerger PG; Panetta CJ; Simari RD; Caplice NM
Thromb Haemost; 2001 Sep; 86(3):923-8. PubMed ID: 11583328
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein Lp(a) and atherothrombotic disease.
de la Peña-Díaz A; Izaguirre-Avila R; Anglés-Cano E
Arch Med Res; 2000; 31(4):353-9. PubMed ID: 11068075
[TBL] [Abstract][Full Text] [Related]
11. Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells.
Ho-Tin-Noé B; Meilhac O; Rossignol P; Lijnen HR; Anglés-Cano E
Thromb Haemost; 2006 Jan; 95(1):142-50. PubMed ID: 16543973
[TBL] [Abstract][Full Text] [Related]
12. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.
Crawley J; Lupu F; Westmuckett AD; Severs NJ; Kakkar VV; Lupu C
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1362-73. PubMed ID: 10807755
[TBL] [Abstract][Full Text] [Related]
13. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
Horie S; Hiraishi S; Hamuro T; Kamikubo Y; Matsuda J
Thromb Haemost; 2002 Jan; 87(1):80-5. PubMed ID: 11848461
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.
Hughes SD; Lou XJ; Ighani S; Verstuyft J; Grainger DJ; Lawn RM; Rubin EM
J Clin Invest; 1997 Sep; 100(6):1493-500. PubMed ID: 9294116
[TBL] [Abstract][Full Text] [Related]
16. The inter-relation of fibrin, lipoprotein(a) and plasminogen in human atherosclerotic lesions.
Smith EB; Crosbie L; Cochran S
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):495-8. PubMed ID: 2151935
[TBL] [Abstract][Full Text] [Related]
17. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Hancock MA; Spencer CA; Koschinsky ML
Biochemistry; 2004 Sep; 43(38):12237-48. PubMed ID: 15379562
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).
Lesnik P; Vonica A; Guérin M; Moreau M; Chapman MJ
Arterioscler Thromb; 1993 Jul; 13(7):1066-75. PubMed ID: 8318508
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts.
Kostner GM; Grillhofer HK
J Biol Chem; 1991 Nov; 266(31):21287-92. PubMed ID: 1834657
[TBL] [Abstract][Full Text] [Related]
20. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.
Caplice NM; Mueske CS; Kleppe LS; Simari RD
Circulation; 1998 Sep; 98(11):1051-7. PubMed ID: 9736590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
